Senzime AB (SEZI) - Total Liabilities
Based on the latest financial reports, Senzime AB (SEZI) has total liabilities worth Skr66.51 Million SEK (≈ $7.16 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Senzime AB - Total Liabilities Trend (2005–2025)
This chart illustrates how Senzime AB's total liabilities have evolved over time, based on quarterly financial data. See Senzime AB short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Senzime AB Competitors by Total Liabilities
The table below lists competitors of Senzime AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AGROB Immobilien AG
F:AGR
|
Germany | €117.93 Million |
|
e-LITECOM CO. Ltd
KQ:041520
|
Korea | ₩10.24 Billion |
|
SRV Group plc
HE:SRV1V
|
Finland | €377.80 Million |
|
Vakrangee Limited
NSE:VAKRANGEE
|
India | Rs1.25 Billion |
|
Cintac
SN:CINTAC
|
Chile | CL$448.56 Million |
|
Shanghai Shibei Hi-Tech Co Ltd B
SHG:900902
|
China | $12.13 Billion |
|
Siebert Financial Corp
NASDAQ:SIEB
|
USA | $509.02 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Senzime AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Senzime AB market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Senzime AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Senzime AB (2005–2025)
The table below shows the annual total liabilities of Senzime AB from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr65.35 Million ≈ $7.03 Million |
-16.94% |
| 2024-12-31 | Skr78.67 Million ≈ $8.47 Million |
+35.49% |
| 2023-12-31 | Skr58.06 Million ≈ $6.25 Million |
-4.46% |
| 2022-12-31 | Skr60.78 Million ≈ $6.54 Million |
+152.80% |
| 2021-12-31 | Skr24.04 Million ≈ $2.59 Million |
-12.72% |
| 2020-12-31 | Skr27.55 Million ≈ $2.96 Million |
+14.45% |
| 2019-12-31 | Skr24.07 Million ≈ $2.59 Million |
-19.10% |
| 2018-12-31 | Skr29.75 Million ≈ $3.20 Million |
+16.33% |
| 2017-12-31 | Skr25.57 Million ≈ $2.75 Million |
+4.63% |
| 2016-12-31 | Skr24.44 Million ≈ $2.63 Million |
+1126.44% |
| 2015-12-31 | Skr1.99 Million ≈ $214.46K |
-10.94% |
| 2014-12-31 | Skr2.24 Million ≈ $240.79K |
+91.47% |
| 2013-12-31 | Skr1.17 Million ≈ $125.76K |
-6.29% |
| 2012-12-31 | Skr1.25 Million ≈ $134.19K |
-67.12% |
| 2011-12-31 | Skr3.79 Million ≈ $408.17K |
-5.82% |
| 2010-12-31 | Skr4.03 Million ≈ $433.39K |
-11.76% |
| 2009-12-31 | Skr4.56 Million ≈ $491.13K |
-5.42% |
| 2008-12-31 | Skr4.83 Million ≈ $519.27K |
+11.44% |
| 2007-12-31 | Skr4.33 Million ≈ $465.98K |
+34.39% |
| 2006-12-31 | Skr3.22 Million ≈ $346.74K |
+7.22% |
| 2005-12-31 | Skr3.00 Million ≈ $323.39K |
-- |
About Senzime AB
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impeda… Read more